EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCAFG00020019390
Gene Symbol: HTR2A
3 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCAFG00020023065
Gene Symbol: HTR2B
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSCAFG00020005051
Gene Symbol: HTR2C
1 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCAFG00020002588
Gene Symbol: HTR3A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCAFG00020002619
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 3c-Like

Ensembl ID : ENSCAFG00020002174
Gene Symbol: LOC112662830
2 Cross references
72 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCAFG00020023454
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSCAFG00020005282
Gene Symbol: HTR5A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCAFG00020000145
Gene Symbol: HTR7
3 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L10a

Ensembl ID : ENSCAFG00020009447
Gene Symbol: LOC112650535
2 Cross references
233 Possible Orthologues:

60s Ribosomal Protein L17

Ensembl ID : ENSCAFG00020002362
Gene Symbol: LOC112647311
2 Cross references
131 Possible Orthologues:

60s Ribosomal Protein L18a

Ensembl ID : ENSCAFG00020020393
Gene Symbol: LOC112665737
2 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).